Novartis Wins Jury Verdict Over Zometa's Bone Death Risk

Law360, New York (May 15, 2013, 2:54 PM EDT) -- A New Jersey jury on Wednesday returned with a verdict for Novartis Pharmaceuticals Corp. in centralized litigation over its bone-strengthening drug Zometa, finding after a 13-day trial that the company did not fail to provide an adequate warning about dead jaw bone risks.

After fewer than six hours of deliberations starting Tuesday afternoon, the eight-member, all-male jury in Middlesex County Superior Court handed down its 7-1 decision in the case of Beverly Meng shortly after 11 a.m. Meng's lawsuit was the second to go on trial...
To view the full article, register now.